$2.29 Billion is the total value of Tekla Capital Management LLC's 192 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 26.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRK | Buy | Merck & Co., Inc. | $101,974,000 | +20.0% | 1,211,384 | +19.5% | 4.45% | +28.3% |
| PFE | Buy | Pfizer Inc. | $75,967,000 | -15.2% | 2,114,306 | +2.2% | 3.31% | -9.4% |
| ILMN | Buy | Illumina, Inc. | $73,359,000 | +0.4% | 241,139 | +21.5% | 3.20% | +7.3% |
| UNH | Buy | Unitedhealth Group Inc. | $73,298,000 | -7.3% | 337,283 | +4.1% | 3.20% | -0.9% |
| BIIB | Buy | Biogen Inc. | $60,053,000 | +14.3% | 257,939 | +14.8% | 2.62% | +22.2% |
| ALXN | Buy | Alexion Pharmaceuticals, Inc. | $44,454,000 | -15.2% | 453,887 | +13.5% | 1.94% | -9.3% |
| ZTS | Buy | Zoetis Inc.class a | $31,026,000 | +10.0% | 249,024 | +0.2% | 1.35% | +17.6% |
| ABBV | Buy | AbbVie Inc. | $30,289,000 | +25.0% | 400,016 | +20.0% | 1.32% | +33.6% |
| ANTM | Buy | Anthem, Inc. | $29,084,000 | -0.4% | 121,132 | +17.1% | 1.27% | +6.5% |
| SYK | Buy | Stryker Corp. | $25,636,000 | +21.1% | 118,520 | +15.1% | 1.12% | +29.4% |
| AGN | Buy | Allergan plcshares | $24,449,000 | +1.2% | 145,281 | +0.7% | 1.07% | +8.2% |
| HUM | Buy | Humana Inc. | $21,536,000 | +68.7% | 84,234 | +75.0% | 0.94% | +80.4% |
| MYL | Buy | Mylan N.V.shares | $20,543,000 | +14.4% | 1,038,554 | +10.1% | 0.90% | +22.2% |
| CI | Buy | Cigna Corp. | $18,973,000 | +3.1% | 124,995 | +7.1% | 0.83% | +10.3% |
| MCK | Buy | McKesson Corp. | $14,659,000 | +14.0% | 107,266 | +12.1% | 0.64% | +21.9% |
| ABC | Buy | AmerisourceBergen Corp. | $14,353,000 | +20.0% | 174,338 | +24.3% | 0.63% | +28.3% |
| ALNY | Buy | Alnylam Pharmaceuticals, Inc. | $13,372,000 | +14.2% | 166,275 | +3.0% | 0.58% | +22.0% |
| BLUE | Buy | Bluebird Bio, Inc. | $12,881,000 | -0.6% | 140,286 | +37.6% | 0.56% | +6.2% |
| SAGE | Buy | Sage Therapeutics Inc | $12,174,000 | -21.0% | 86,780 | +3.1% | 0.53% | -15.6% |
| HCA | Buy | HCA Healthcare, Inc. | $11,848,000 | -2.1% | 98,393 | +9.9% | 0.52% | +4.7% |
| IONS | Buy | Ionis Pharmaceuticals, Inc. | $11,158,000 | +36.1% | 186,244 | +46.0% | 0.49% | +45.4% |
| VTR | Buy | Ventas, Inc. | $10,306,000 | +53.1% | 141,119 | +43.3% | 0.45% | +63.6% |
| GSK | Buy | GlaxoSmithKline PLCshares | $9,891,000 | +13.0% | 231,758 | +6.0% | 0.43% | +21.0% |
| JAZZ | Buy | Jazz Pharmaceuticals plcshares | $9,602,000 | -0.2% | 74,936 | +11.1% | 0.42% | +6.6% |
| ESPR | Buy | Esperion Therapeutics, Inc. | $7,829,000 | -8.8% | 213,562 | +15.7% | 0.34% | -2.3% |
| NVCR | Buy | Novocure Ltd.ordinary shares | $7,548,000 | +120.8% | 100,932 | +86.7% | 0.33% | +135.0% |
| ASND | Buy | Ascendis Pharma A/Ssponsored adr | $7,433,000 | -12.3% | 77,167 | +4.8% | 0.32% | -6.4% |
| BPMC | Buy | Blueprint Medicines Corp. | $7,414,000 | -17.2% | 100,916 | +6.3% | 0.32% | -11.7% |
| XRAY | Buy | DENTSPLY SIRONA Inc. | $7,300,000 | -1.4% | 136,936 | +7.9% | 0.32% | +5.3% |
| IMMU | Buy | Immunomedics, Inc. | $6,459,000 | +19.6% | 487,103 | +25.1% | 0.28% | +28.2% |
| MRTX | Buy | Mirati Therapeutics, Inc. | $6,208,000 | +343.4% | 79,687 | +486.4% | 0.27% | +375.4% |
| TECH | Buy | Bio-Techne Corp. | $5,975,000 | +32.1% | 30,537 | +40.7% | 0.26% | +41.1% |
| HZNP | Buy | Horizon Therapeutics plcshares | $5,847,000 | +54.3% | 214,730 | +36.4% | 0.26% | +64.5% |
| PTCT | Buy | PTC Therapeutics, Inc. | $5,020,000 | -20.1% | 148,435 | +6.3% | 0.22% | -14.5% |
| XNCR | Buy | Xencor, Inc. | $5,000,000 | +68.7% | 148,231 | +104.8% | 0.22% | +80.2% |
| GBT | Buy | Global Blood Therapeutics, Inc. | $4,510,000 | +27.0% | 92,957 | +37.7% | 0.20% | +35.9% |
| IQV | Buy | IQVIA Holdings Inc. | $4,460,000 | +69.1% | 29,857 | +82.2% | 0.20% | +80.6% |
| RARE | Buy | Ultragenyx Pharmaceutical Inc. | $4,170,000 | +70.7% | 97,480 | +153.3% | 0.18% | +82.0% |
| RGNX | Buy | REGENXBIO Inc. | $3,889,000 | +491.0% | 109,248 | +753.4% | 0.17% | +529.6% |
| ARGX | Buy | Argenx SEsponsored adr | $3,880,000 | -3.4% | 34,048 | +20.0% | 0.17% | +3.0% |
| TAK | Buy | Takeda Pharmaceuticsponsored ads | $3,615,000 | +14.7% | 210,146 | +18.0% | 0.16% | +22.5% |
| EDIT | Buy | Editas Medicine, Inc. | $3,364,000 | +202.2% | 147,939 | +228.8% | 0.15% | +226.7% |
| CRL | Buy | Charles River Laboratories International, Inc. | $3,318,000 | +65.1% | 25,067 | +76.9% | 0.14% | +76.8% |
| INGN | Buy | Inogen, Inc. | $2,948,000 | +215.3% | 61,526 | +339.5% | 0.13% | +239.5% |
| INSM | New | Insmed Inc. | $2,907,000 | – | 164,786 | +100.0% | 0.13% | – |
| CAH | Buy | Cardinal Health, Inc. | $2,748,000 | +825.3% | 58,241 | +824.5% | 0.12% | +900.0% |
| A | Buy | Agilent Technologies, Inc. | $2,607,000 | +3.9% | 34,025 | +1.3% | 0.11% | +11.8% |
| PACB | New | Pacific Biosciences of California, Inc. | $2,557,000 | – | 495,495 | +100.0% | 0.11% | – |
| WMGI | Buy | Wright Medical Group N.V.ordinary shares | $2,558,000 | +25.2% | 124,006 | +81.0% | 0.11% | +34.9% |
| FATE | Buy | Fate Therapeutics, Inc. | $2,573,000 | +419.8% | 165,672 | +579.6% | 0.11% | +460.0% |
| WVE | Buy | WaVe Life Sciences Ltd.shares | $2,516,000 | +72.3% | 122,551 | +119.0% | 0.11% | +83.3% |
| SYNH | Buy | Syneos Health, Inc.class a | $2,447,000 | +65.0% | 45,982 | +58.4% | 0.11% | +75.4% |
| RCKT | New | Rocket Pharmaceuticals, Inc. | $2,418,000 | – | 207,555 | +100.0% | 0.10% | – |
| APLS | New | Apellis Pharmaceuticals, Inc. | $2,380,000 | – | 98,784 | +100.0% | 0.10% | – |
| QTNT | New | Quotient Ltd. | $2,020,000 | – | 260,030 | +100.0% | 0.09% | – |
| IBB | New | iShares Nasdaq Biotechnology ETFnasdaq biotech | $1,882,000 | – | 18,914 | +100.0% | 0.08% | – |
| QURE | Buy | uniQure B.V.shares | $1,726,000 | +11.8% | 43,849 | +122.0% | 0.08% | +19.0% |
| EVH | Buy | Evolent Health, Inc. | $1,661,000 | +19.9% | 231,027 | +32.6% | 0.07% | +26.3% |
| PKI | New | PerkinElmer, Inc. | $1,619,000 | – | 19,011 | +100.0% | 0.07% | – |
| RARX | Buy | Ra Pharmaceuticals, Inc. | $1,320,000 | +128.8% | 55,829 | +190.9% | 0.06% | +141.7% |
| ZLAB | New | Zai Lab Ltd.adr | $1,214,000 | – | 37,523 | +100.0% | 0.05% | – |
| BHVN | New | Biohaven Pharmaceutical Holding Company Ltd. | $1,215,000 | – | 29,125 | +100.0% | 0.05% | – |
| TBPH | New | Theravance Biopharma, Inc. | $898,000 | – | 46,101 | +100.0% | 0.04% | – |
| ZYME | New | Zymeworks Inc. | $377,000 | – | 15,192 | +100.0% | 0.02% | – |
| AVRO | New | AVROBIO, Inc. | $285,000 | – | 20,176 | +100.0% | 0.01% | – |
| TTPH | New | Tetraphase Pharmaceuticals, Inc. | $229,000 | – | 42,966 | +100.0% | 0.01% | – |
| MGTA | New | Magenta Therapeutics, Inc. | $172,000 | – | 16,757 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.